retatrutide efficacy weight loss and Safety of GLP‐1 Receptor Agonists, Dual Agonists, and for in Adults With Overweight or Obesity: A Bayesian NMA - Sinha - 2025 - Obesity Retatrutide Half Life: A Doctor

Reporting Adverse Events Seek Medical Care If you experience severe side effects or adverse events (e.g., difficulty breathing, severe allergic reactions, acute hypoglycemia), discontinue use and seek immediate medical attention

Federal law prohibits Medicare from covering weight loss medications

Patients seeking GLP-1 therapy should only obtain medications through legitimate healthcare channelsprescribed by a registered healthcare professional and dispensed by a General Pharmaceutical Council (GPhC) or Pharmaceutical Society of Northern Ireland (PSNI) registered pharmacy

Too little would negate the metabolic benefits

Researchers in 2026 should evaluate both compounds against current Phase 3 data as it becomes available

This leads to the conclusion that using a drug to lose weight is somehow cheating, or taking the easy way out, and we shouldnt be spending NHS money on something people could fix themselves